BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA. Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. Front Oncol 2019;9:1186. [PMID: 31788449 DOI: 10.3389/fonc.2019.01186] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 20.3] [Reference Citation Analysis]
Number Citing Articles
1 Frank B, Guo H, Lebrec H, Wang X. Application of a newly-developed cynomolgus macaque BiTE-mediated cytotoxic T-lymphocyte activity assay to various immunomodulatory agents in vitro. J Immunotoxicol 2021;18:154-62. [PMID: 34714999 DOI: 10.1080/1547691X.2021.1992687] [Reference Citation Analysis]
2 Longhitano L, Tibullo D, Giallongo C, Lazzarino G, Tartaglia N, Galimberti S, Li Volti G, Palumbo GA, Liso A. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. Int J Mol Sci 2020;21:E3622. [PMID: 32443911 DOI: 10.3390/ijms21103622] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
3 Rodrigues PRS, Alrubayyi A, Pring E, Bart VMT, Jones R, Coveney C, Lu F, Tellier M, Maleki-Toyserkani S, Richter FC, Scourfield DO, Gea-Mallorquí E, Davies LC. Innate immunology in COVID-19-a living review. Part II: dysregulated inflammation drives immunopathology. Oxf Open Immunol 2020;1:iqaa005. [PMID: 34192268 DOI: 10.1093/oxfimm/iqaa005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Botta C, Indrieri A, Garofalo E, Biamonte F, Bruni A, Pasqua P, Cesario F, Costanzo FS, Longhini F, Mendicino F. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm. Front Oncol 2020;10:599502. [PMID: 33489899 DOI: 10.3389/fonc.2020.599502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Alqarni AM, Zeidler MP. How does methotrexate work? Biochemical Society Transactions 2020;48:559-67. [DOI: 10.1042/bst20190803] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
6 Xu B, Tang B, Wei J. Role of STAT1 in the resistance of HBV to IFN-α. Exp Ther Med 2021;21:550. [PMID: 33850522 DOI: 10.3892/etm.2021.9982] [Reference Citation Analysis]
7 Sarmiento M, Rojas P, Jerez J, Bertín P, Campbell J, García MJ, Pereira J, Triantafilo N, Ocqueteau M. Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids. Acta Haematol 2021;144:620-6. [PMID: 34111867 DOI: 10.1159/000516464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Kumar P, Sah AK, Tripathi G, Kashyap A, Tripathi A, Rao R, Mishra PC, Mallick K, Husain A, Kashyap MK. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Mol Cell Biochem 2021;476:553-74. [PMID: 33029696 DOI: 10.1007/s11010-020-03924-2] [Reference Citation Analysis]
9 Blakney AK, Ip S, Geall AJ. An Update on Self-Amplifying mRNA Vaccine Development. Vaccines (Basel) 2021;9:97. [PMID: 33525396 DOI: 10.3390/vaccines9020097] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
10 Iurlo A, Cattaneo D, Bucelli C. Management of Myelofibrosis: from Diagnosis to New Target Therapies. Curr Treat Options in Oncol 2020;21. [DOI: 10.1007/s11864-020-00734-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Rojas P, Sarmiento M. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients. Acta Haematol 2021;144:314-8. [PMID: 32726783 DOI: 10.1159/000510179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
12 Spini A, Giudice V, Brancaleone V, Morgese MG, De Francia S, Filippelli A, Ruggieri A, Ziche M, Ortona E, Cignarella A, Trabace L. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res 2021;173:105848. [PMID: 34454035 DOI: 10.1016/j.phrs.2021.105848] [Reference Citation Analysis]
13 Sadjadian P, Wille K, Griesshammer M. Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations. Cancers (Basel) 2020;12:E3132. [PMID: 33114733 DOI: 10.3390/cancers12113132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y, Shimura Y, Kobayashi T, Horiike S, Kuroda J. Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib. Infect Drug Resist 2020;13:1017-21. [PMID: 32308443 DOI: 10.2147/IDR.S249030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Holmström MO, Hasselbalch HC, Andersen MH. Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers (Basel) 2020;12:E1763. [PMID: 32630667 DOI: 10.3390/cancers12071763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lee YP, Jeong BH, Eun Y, Kang CI, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. Eur J Cancer 2021;159:167-73. [PMID: 34753013 DOI: 10.1016/j.ejca.2021.09.037] [Reference Citation Analysis]
17 Heiblig M, Patel BA, Groarke EM, Bourbon E, Sujobert P. Toward a pathophysiology inspired treatment of VEXAS syndrome. Semin Hematol 2021;58:239-46. [PMID: 34802546 DOI: 10.1053/j.seminhematol.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cook J, Acosta-Medina AA, Peng KW, Lacy M, Russell S. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. Cancer Treat Res Commun 2021;29:100473. [PMID: 34673439 DOI: 10.1016/j.ctarc.2021.100473] [Reference Citation Analysis]
19 Blakney AK, McKay PF, Bouton CR, Hu K, Samnuan K, Shattock RJ. Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. Mol Ther 2021;29:1174-85. [PMID: 33352107 DOI: 10.1016/j.ymthe.2020.11.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Li B, Wan Q, Li Z, Chng WJ. Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers. Cancers (Basel) 2021;13:5147. [PMID: 34680295 DOI: 10.3390/cancers13205147] [Reference Citation Analysis]
21 Pryimak N, Zaiachuk M, Kovalchuk O, Kovalchuk I. The Potential Use of Cannabis in Tissue Fibrosis. Front Cell Dev Biol 2021;9:715380. [PMID: 34708034 DOI: 10.3389/fcell.2021.715380] [Reference Citation Analysis]
22 Spampinato M, Giallongo C, Romano A, Longhitano L, La Spina E, Avola R, Scandura G, Dulcamare I, Bramanti V, Di Rosa M, Vicario N, Parenti R, Li Volti G, Tibullo D, Palumbo GA. Focus on Osteosclerotic Progression in Primary Myelofibrosis. Biomolecules 2021;11:122. [PMID: 33477816 DOI: 10.3390/biom11010122] [Reference Citation Analysis]
23 Ibrahim A, Noun P, Khalil C, Taher A. Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion. Front Oncol 2021;11:564383. [PMID: 33791197 DOI: 10.3389/fonc.2021.564383] [Reference Citation Analysis]
24 Wang D, Liu Y, Lai X, Chen J, Cheng Q, Ma X, Lin Z, Wu D, Xu Y. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. Front Immunol 2021;12:673636. [PMID: 34276662 DOI: 10.3389/fimmu.2021.673636] [Reference Citation Analysis]
25 Vandenhove B, Canti L, Schoemans H, Beguin Y, Baron F, Graux C, Kerre T, Servais S. How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. Front Immunol 2020;11:583564. [PMID: 33193397 DOI: 10.3389/fimmu.2020.583564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Cattaneo D, Iurlo A. Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors. Front Immunol 2021;12:750346. [PMID: 34867980 DOI: 10.3389/fimmu.2021.750346] [Reference Citation Analysis]
27 Magro G. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res 2020;286:198070. [PMID: 32569708 DOI: 10.1016/j.virusres.2020.198070] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 27.0] [Reference Citation Analysis]
28 Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, Chevallier P, Mohty M, Passweg J, Rubio MT, Maertens J, Finke J, Bornhäuser M, Vrhovac R, Helbig G, Mear JB, Castagna L, Reményi P, Angelucci E, Karakasis D, Rifòn J, Sirait T, Russo D, de Wreede L, Czerw T, Hernández-Boluda JC, Hayden P, McLornan D, Yakoub-Agha I. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol 2021;96:69-79. [PMID: 33064301 DOI: 10.1002/ajh.26020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
29 Dettorre GM, Patel M, Gennari A, Pentheroudakis G, Romano E, Cortellini A, Pinato DJ. The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. ESMO Open 2021;6:100123. [PMID: 33932622 DOI: 10.1016/j.esmoop.2021.100123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM, Gammaldi R, Maglio A, Sellitto C, Vitale C, Serio B, Cuffa B, Borrelli A, Vecchione C, Filippelli A, Selleri C. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. Front Pharmacol 2020;11:857. [PMID: 32581810 DOI: 10.3389/fphar.2020.00857] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 27.0] [Reference Citation Analysis]
31 Hasselbalch HC, Skov V, Kjær L, Ellervik C, Poulsen A, Poulsen TD, Nielsen CH. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev 2021;60:28-45. [PMID: 33992887 DOI: 10.1016/j.cytogfr.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Smail SW, Saeed M, Twana Alkasalias, Khudhur ZO, Younus DA, Rajab MF, Abdulahad WH, Hussain HI, Niaz K, Safdar M. Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. Food Chem Toxicol 2021;150:112087. [PMID: 33640537 DOI: 10.1016/j.fct.2021.112087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Parenti S, Rontauroli S, Carretta C, Mallia S, Genovese E, Chiereghin C, Peano C, Tavernari L, Bianchi E, Fantini S, Sartini S, Romano O, Bicciato S, Tagliafico E, Della Porta M, Manfredini R. Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis. NPJ Precis Oncol 2021;5:4. [PMID: 33542466 DOI: 10.1038/s41698-021-00144-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, Naumovas D, Banys V, Pečeliūnas V, Beinortas T, Griškevičius L. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol 2021;8:e583-92. [PMID: 34224668 DOI: 10.1016/S2352-3026(21)00169-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
35 Malato A, Rossi E, Palumbo GA, Guglielmelli P, Pugliese N. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review. Int J Mol Sci 2020;21:E3900. [PMID: 32486130 DOI: 10.3390/ijms21113900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Deveci B, Saba R, Altunay H, Toptas T, Kublashvilli G, Karadogan I. Severe Acute Hemolytic Transfusion Reaction Treated with Ruxolitinib and Plasma Exchange. Transfus Med Hemother 2021;48:250-3. [PMID: 34539320 DOI: 10.1159/000513056] [Reference Citation Analysis]
37 Kumar P, Sah AK, Tripathi G, Kashyap A, Tripathi A, Rao R, Mishra PC, Mallick K, Husain A, Kashyap MK. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Mol Cell Biochem 2021;476:553-74. [PMID: 33029696 DOI: 10.1007/s11010-020-03924-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
38 Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol 2021. [PMID: 34423443 DOI: 10.1111/ijd.15853] [Reference Citation Analysis]
39 Breccia M, Piciocchi A, De Stefano V, Finazzi G, Iurlo A, Fazi P, Soddu S, Martino B, Palandri F, Siragusa S, Albano F, Passamonti F, Vignetti M, Vannucchi AM. COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. Leukemia 2020;34:2813-4. [PMID: 32843716 DOI: 10.1038/s41375-020-01032-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
40 Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. Int J Mol Sci 2021;22:6211. [PMID: 34207510 DOI: 10.3390/ijms22126211] [Reference Citation Analysis]
41 Segura-Díaz A, Stuckey R, Florido Y, González-Martín JM, López-Rodríguez JF, Sánchez-Sosa S, González-Pérez E, Sáez Perdomo MN, Perera MDM, de la Iglesia S, Molero-Labarta T, Gómez-Casares MT, Bilbao-Sieyro C. Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations. Cancers (Basel) 2020;12:E934. [PMID: 32290079 DOI: 10.3390/cancers12040934] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
42 Zimmermann S, Aghai F, Schilling B, Kraus S, Grigoleit GU, Kalogirou C, Goebeler M, Jung P, Pelzer T, Klinker H, Isberner N, Scherf-clavel O. Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio. Journal of Pharmaceutical and Biomedical Analysis 2022. [DOI: 10.1016/j.jpba.2022.114623] [Reference Citation Analysis]
43 Stella S, Massimino M, Manzella L, Pennisi MS, Tirrò E, Romano C, Vitale SR, Puma A, Tomarchio C, Gregorio SD, Palumbo GA, Vigneri P. Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes. Int J Mol Sci 2021;22:E486. [PMID: 33418988 DOI: 10.3390/ijms22020486] [Reference Citation Analysis]
44 Klaeschen AS, Nümm TJ, Herrmann N, Leib N, Maintz L, Sakai T, Wenzel J, Bieber T. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. J Allergy Clin Immunol 2021;147:2202-2212.e8. [PMID: 33338537 DOI: 10.1016/j.jaci.2020.11.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol 2021;193:356-68. [PMID: 33222197 DOI: 10.1111/bjh.17192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Haddad N, Delyon J, Trabelsi Messai S, Herms F, Leccia MT, Lebbe C, Whitney J, Bhatia S, Basset-Seguin N. Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. Br J Dermatol 2021;184:564-6. [PMID: 33058221 DOI: 10.1111/bjd.19604] [Reference Citation Analysis]
47 Di Rosa M, Giallongo C, Romano A, Tibullo D, Li Volti G, Musumeci G, Barbagallo I, Imbesi R, Castrogiovanni P, Palumbo GA. Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients. Int J Mol Sci 2020;21:E2926. [PMID: 32331228 DOI: 10.3390/ijms21082926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ibrahim U, Petrone GEM, Mascarenhas J, Keyzner A. Peritransplantation Use of Ruxolitinib in Myelofibrosis. Biol Blood Marrow Transplant 2020;26:2177-80. [PMID: 32818555 DOI: 10.1016/j.bbmt.2020.08.015] [Reference Citation Analysis]
49 Palumbo GA, Galimberti S, Barcellini W, Cilloni D, Di Renzo N, Elli EM, Finelli C, Maurillo L, Ricco A, Musto P, Russo R, Latagliata R. From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. Front Oncol 2021;11:752192. [PMID: 34692534 DOI: 10.3389/fonc.2021.752192] [Reference Citation Analysis]
50 Siegler EL, Kenderian SS. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Front Immunol 2020;11:1973. [PMID: 32983132 DOI: 10.3389/fimmu.2020.01973] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
51 Turgutkaya A, Yavaşoğlu İ. [Ruxolitinib induced leukocytoclastic vasculitis]. Med Clin (Barc) 2021;157:501. [PMID: 33386115 DOI: 10.1016/j.medcli.2020.11.014] [Reference Citation Analysis]
52 Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Llunell A, Miró-Mur F. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev 2020;19:102569. [PMID: 32376394 DOI: 10.1016/j.autrev.2020.102569] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 44.0] [Reference Citation Analysis]
53 Guo P, Liu Y, Geng F, Daman AW, Liu X, Zhong L, Ravishankar A, Lis R, Barcia Durán JG, Itkin T, Tang F, Zhang T, Xiang J, Shido K, Ding BS, Wen D, Josefowicz SZ, Rafii S. Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nat Cell Biol 2021. [PMID: 34961794 DOI: 10.1038/s41556-021-00795-7] [Reference Citation Analysis]
54 Buonerba L, Di Trolio R, Grimaldi A, Tucci A, Leo E, Ingenito C, Costabile F, Ragone G, Savastano B, Uzzauto MT, Belsito Petrizzi V, Di Lorenzo G. Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma. Front Oncol 2020;10:579914. [PMID: 33194706 DOI: 10.3389/fonc.2020.579914] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Zhu H, Jian Z, Zhong Y, Ye Y, Zhang Y, Hu X, Pu B, Gu L, Xiong X. Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition. Front Immunol 2021;12:714943. [PMID: 34367186 DOI: 10.3389/fimmu.2021.714943] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Skov V. Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers (Basel) 2020;12:E2194. [PMID: 32781570 DOI: 10.3390/cancers12082194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Re D, Barrière J, Chamorey E, Delforge M, Gastaud L, Petit E, Chaminade A, Verrière B, Peyrade F. Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies. Leuk Lymphoma 2021;62:3308-10. [PMID: 34308748 DOI: 10.1080/10428194.2021.1957877] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
58 Jarai BM, Stillman Z, Bomb K, Kloxin AM, Fromen CA. Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. ACS Biomater Sci Eng 2021;7:1742-64. [PMID: 33356134 DOI: 10.1021/acsbiomaterials.0c01287] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
59 Sayabovorn N, Chongtrakool P, Chayakulkeeree M. Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review. BMC Infect Dis 2021;21:27. [PMID: 33413168 DOI: 10.1186/s12879-020-05703-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Wei C, Zhang X, Liang D, Yang J, Du J, Yue C, Deng L. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients. Drug Des Devel Ther 2021;15:4875-83. [PMID: 34880598 DOI: 10.2147/DDDT.S338752] [Reference Citation Analysis]
61 Hosseinikhah SM, Barani M, Rahdar A, Madry H, Arshad R, Mohammadzadeh V, Cucchiarini M. Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis. Int J Mol Sci 2021;22:3092. [PMID: 33803502 DOI: 10.3390/ijms22063092] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Giordano G, Napolitano M, Cellurale M, Di Carlo P, Musuraca G, Micucci G, Lucchesi A. Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms. JPM 2022;12:364. [DOI: 10.3390/jpm12030364] [Reference Citation Analysis]
63 Słuczanowska-Głąbowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J Clin Med 2021;10:4307. [PMID: 34640327 DOI: 10.3390/jcm10194307] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Naismith E, Steichen J, Sopper S, Wolf D. NK Cells in Myeloproliferative Neoplasms (MPN). Cancers (Basel) 2021;13:4400. [PMID: 34503210 DOI: 10.3390/cancers13174400] [Reference Citation Analysis]
65 Palandri F, Piciocchi A, De Stefano V, Breccia M, Finazzi G, Iurlo A, Fazi P, Soddu S, Martino B, Siragusa S, Albano F, Passamonti F, Vignetti M, Vannucchi AM. How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey. Leukemia 2020;34:2805-8. [PMID: 32620840 DOI: 10.1038/s41375-020-0953-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
66 Palandri F, Breccia M, De Stefano V, Passamonti F. Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. Cancers (Basel) 2021;13:4750. [PMID: 34638236 DOI: 10.3390/cancers13194750] [Reference Citation Analysis]
67 Heine A, Wolf AM, Schlaweck S, Daecke SN, Brossart P, Wolf D. Pacritinib protects dendritic cells more efficiently than ruxolitinib. Exp Hematol 2021;100:37-40. [PMID: 34182006 DOI: 10.1016/j.exphem.2021.06.004] [Reference Citation Analysis]
68 Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. Molecules 2020;25:E3321. [PMID: 32707925 DOI: 10.3390/molecules25153321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
69 Al-Horani RA, Kar S, Aliter KF. Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. Int J Mol Sci 2020;21:E5224. [PMID: 32718020 DOI: 10.3390/ijms21155224] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
70 Quiros JR, Ross-Comptis J, Hathaway D 3rd, Sarfraz A, Sarfraz Z, Grigoryan Z, Romero KA, Gapizov A, Príncipe-Meneses FS, Somagutta MR, Riva-Moscoso A, Kapasi A. Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis. Infect Chemother 2021;53:436-48. [PMID: 34623777 DOI: 10.3947/ic.2020.0126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov Z. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica 2021;106:2384-96. [PMID: 32732359 DOI: 10.3324/haematol.2020.249441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Ovsyannikova G, Balashov D, Demina I, Shelikhova L, Pshonkin A, Maschan M, Novichkova G, Maschan A, Smetanina N. Efficacy and safety of ruxolitinib in ineffective erythropoiesis suppression as a pretransplantation treatment for pediatric patients with beta-thalassemia major. Pediatr Blood Cancer 2021;68:e29338. [PMID: 34520107 DOI: 10.1002/pbc.29338] [Reference Citation Analysis]
73 McKechnie JL, Blish CA. The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19? Cell Host Microbe 2020;27:863-9. [PMID: 32464098 DOI: 10.1016/j.chom.2020.05.009] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 43.0] [Reference Citation Analysis]
74 Mohammadi Barzelighi H, Daraei B, Dastan F. Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review. Iran J Pharm Res 2020;19:258-81. [PMID: 33680028 DOI: 10.22037/ijpr.2020.113821.14506] [Reference Citation Analysis]
75 Longhitano L, Li Volti G, Giallongo C, Spampinato M, Barbagallo I, Di Rosa M, Romano A, Avola R, Tibullo D, Palumbo GA. The Role of Inflammation and Inflammasome in Myeloproliferative Disease. J Clin Med 2020;9:E2334. [PMID: 32707883 DOI: 10.3390/jcm9082334] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
76 Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;80:1267-1292. [PMID: 32696108 DOI: 10.1007/s40265-020-01367-z] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 40.5] [Reference Citation Analysis]
77 Kuykendall AT, Horvat NP, Pandey G, Komrokji R, Reuther GW. Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers (Basel) 2020;12:E2278. [PMID: 32823910 DOI: 10.3390/cancers12082278] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]